TEX12 Antibody

What is TEX12 and what is its normal biological function?

TEX12 (Testis Expressed 12) is a 14 kDa protein that functions as a component of the transverse central element of synaptonemal complexes (SCs) formed between homologous chromosomes during meiotic prophase. It requires SYCP1 to be incorporated into the central element of the SC . In prophase I stage of meiosis, TEX12 localizes in the transverse central elements of the central region between lateral elements of the synaptonemal complexes and is found only where chromosome cores are synapsed . Recent research has identified that TEX12 also localizes to centrin-rich bodies in meiosis, which may be precursors of mitotic centrosomes, suggesting an additional cellular function that was previously overlooked .

What applications are TEX12 antibodies validated for?

TEX12 antibodies have been validated for multiple applications, with variation between commercial sources:

Most antibodies are polyclonal and have been affinity-purified for enhanced specificity .

How should TEX12 antibodies be stored for optimal performance?

For short-term storage (up to 2 weeks), TEX12 antibodies should be maintained at 4°C. For long-term storage, aliquot and store at -20°C to prevent freeze-thaw cycles that can degrade antibody quality . Most commercial TEX12 antibodies are supplied in PBS buffer (pH 7.2-7.3) containing 0.02% sodium azide and 40-50% glycerol as preservatives . Small aliquots are recommended to avoid repeated freeze-thaw cycles, which can significantly reduce antibody activity .

What are the recommended dilutions for TEX12 antibody applications?

Optimal dilutions vary by application and supplier:

These dilutions should be optimized for each experimental system, as the optimal concentration may vary based on tissue type, fixation method, and detection system used .

What controls should be included when using TEX12 antibodies in cancer research?

When designing TEX12 antibody experiments for cancer research, several critical controls should be included:

• Positive control: Include TEX12-expressing tissues (testis) or cell lines with confirmed TEX12 expression .

• Negative control: Use TEX12-negative cell lines such as PEO1 cancer cells or non-transformed fibroblasts, which have been shown not to express TEX12 .

• siRNA knockdown control: TEX12 silencing has been validated in multiple cancer cell lines including MX1 cells, with RT-qPCR confirming knockdown efficacy and suitability as a specificity control .

• Overexpression control: COS7 cells transfected with TEX12 expression vector have been used to validate antibody specificity compared to empty vector controls .

• Secondary antibody-only control: To assess background staining in immunofluorescence applications.

Research by Feichtinger et al. demonstrated that TEX12 siRNA knockdown reduced proliferation in multiple cancer cell lines but had no effect on TEX12-negative cells, providing an important functional validation approach .

How can I validate the specificity of a TEX12 antibody for my experimental model?

To validate TEX12 antibody specificity in your experimental model:

• Western blot validation: Confirm a single band at the expected molecular weight of 14 kDa. Several studies have confirmed this as the observed molecular weight for TEX12 .

• Knockout/knockdown validation: Compare staining between control and TEX12-silenced samples. Supplementary Figure 2b in Feichtinger et al. validated their TEX12 antibody by treating MX-1 cells with control siRNA or siTEX12 for 96h followed by immunofluorescence .

• Overexpression validation: Express TEX12 in a negative cell line. COS7 cells transfected with TEX12 showed specific staining compared to empty vector controls (Supplementary Figure 2a,c) .

• Peptide competition: Pre-incubate the antibody with the immunizing peptide to confirm signal reduction.

• Cross-reactivity testing: Test antibody reactivity with closely related proteins if appropriate.

Several commercial TEX12 antibodies have undergone extensive validation. For example, one antibody was verified on a protein array containing the target protein plus 383 other non-specific proteins to confirm specificity .

Which TEX12 antibody epitopes are most suitable for detecting centrosomal localization?

For detecting centrosomal localization of TEX12, antibodies targeting the central region (amino acids 34-63) have been successfully used in immunofluorescence applications . This region appears to be accessible when TEX12 is localized to centrosomes in cancer cells. In the study by Feichtinger et al., TEX12 was consistently detected in dot-like peri-nuclear foci that co-localized with both centrin and pericentrin, confirming its recruitment to centrosomes .

When selecting an antibody for centrosomal detection, consider:

• Select antibodies validated for immunofluorescence applications.

• Consider antibodies raised against the central region of TEX12 (AA 34-63).

• Confirm centrosomal localization with co-staining for established centrosomal markers like pericentrin or γ-tubulin .

It's worth noting that FLAG-tagged TEX12 expressed in TEX12-negative COS7 cells also co-localized with pericentrin in dot-like foci, suggesting that epitope tags do not interfere with centrosomal localization .

What sample preparation methods are optimal for TEX12 detection in different tissue types?

Sample preparation methods vary by tissue type and application:

For immunohistochemistry in testis tissue:

• Paraffin-embedded sections work well with antigen retrieval.

• TE buffer pH 9.0 is recommended for antigen retrieval, although citrate buffer pH 6.0 may be used as an alternative .

• Dilutions between 1:50-1:500 have been successful (Proteintech recommendation) .

For cancer tissue immunohistochemistry:

• Formalin-fixed paraffin-embedded sections have been used successfully.

• In mouse models of lymphoma and hepatocellular carcinoma, TEX12 was successfully detected in tumor tissues by IHC .

For cell lines in immunofluorescence:

• Standard PFA fixation (4%) followed by permeabilization with 0.1-0.5% Triton X-100.

• When examining centrosomal localization, co-staining with centrosomal markers is recommended .

For Western blot:

• Standard RIPA or NP-40 lysis buffers are suitable.

• Sample preparation in reducing SDS sample buffer with heat denaturation.

• Expect to observe a band at approximately 14 kDa .

How does TEX12 localization differ between meiotic cells and cancer cells?

TEX12 shows distinct localization patterns in meiotic versus cancer cells:

In meiotic cells:

• Primarily localizes to synaptonemal complexes between homologous chromosomes during prophase I .

• Found only where chromosome cores are synapsed .

• Recently identified in meiotic centrin-rich bodies, likely precursors of mitotic centrosomes .

• During prophase-I, two TEX12 foci partially overlap with bright γ-tubulin signals .

• In diakinesis/metaphase-I, TEX12 toroids appear to encircle γ-tubulin structures .

In cancer cells:

• Localizes to dot-like peri-nuclear foci that co-localize with centrosomal markers (centrin and pericentrin) .

• Associated with rosette centrosomes, a feature common in cancer cells .

• Contributes to centrosome amplification and structural stability .

• Remains localized to centrosomes independent of its function in the synaptonemal complex .

This dichotomy resembles observations in fungal sexual cycles where certain proteins first participate in SC formation and later localize to spindle pole bodies . The research suggests that TEX12's role in centrosomes may represent a previously overlooked pseudo-meiotic function that is reactivated in cancer cells .

What is the mechanism by which TEX12 contributes to centrosome amplification in cancer?

The mechanism of TEX12's contribution to centrosome amplification involves:

These findings suggest that TEX12's role in centrosome amplification may be central to its pro-oncogenic function and association with poor prognosis in certain cancers .

How can TEX12 expression be correlated with patient prognosis in different cancer types?

TEX12 expression correlates with patient prognosis in several cancer types, though the relationship varies:

• Ovarian cancer: TEX12 amplification correlates with remarkably poor prognosis, with absence of any long-term survivors in the TEX12-amplified cohort. This represents the most striking correlation observed .

• Glioblastoma: Similar to ovarian cancer, TEX12 amplification correlates with poor survival .

• Other cancers with positive correlation: Kidney renal clear cell carcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma all show correlation between TEX12 amplification and poor survival .

• Cancers without correlation: In prostate cancer, TEX12 expression levels are unrelated to survival .

To correlate TEX12 expression with prognosis:

• Transcriptomic analysis: Large-scale transcriptomic analysis of patient material can identify TEX12 expression and amplification .

• Immunohistochemistry: Can be used to assess TEX12 protein expression in patient samples. In mouse models, high lymph node expression of Tex12 correlated with more aggressive disease and shortened survival .

• Early diagnostic potential: In a DEN-induced mouse model of hepatocellular carcinoma, Tex12 expression was detected as early as five weeks following treatment, indicating its expression at very early stages of oncogenesis, prior to overt tumor formation .

These findings highlight TEX12's potential as both a prognostic marker and an early diagnostic marker in specific cancer types .

What is the relationship between TEX12 expression and cellular proliferation in cancer models?

TEX12 expression is strongly linked to cancer cell proliferation:

• siRNA knockdown effects: TEX12 silencing abrogated cellular proliferation in multiple cancer cell lines, with failure to increase cell numbers when cultured for up to seven days .

• Cell-type specificity: TEX12-negative PEO1 cancer cells and non-transformed fibroblasts showed no response to TEX12 silencing, indicating the effect is specific to TEX12-expressing cancer cells .

• Mechanism distinction: The proliferative defect was confirmed not to be simply due to cell death, establishing that TEX12 is specifically required for cell proliferation .

• Early oncogenesis role: In mouse models of hepatocellular carcinoma, Tex12 expression was detected at very early stages (five weeks following DEN treatment), suggesting it may be a driver of early oncogenesis .

• Centrosome connection: The proliferative function of TEX12 appears to be linked to its role in centrosome amplification, as centrosome amplification has been shown to be sufficient to initiate tumorigenesis .

These findings establish TEX12 as a critical factor for cellular proliferation in TEX12-expressing cancers, potentially through its effects on centrosome structure and number .

Why might I observe different molecular weights for TEX12 in Western blot analysis?

While the expected molecular weight of TEX12 is 14 kDa, discrepancies may occur for several reasons:

• Post-translational modifications: Potential phosphorylation or other modifications may alter the apparent molecular weight.

• Protein isoforms: The UniProt database indicates secondary accession numbers (A6NDL9, B0YIX3) suggesting potential isoforms of TEX12 that might display different migration patterns .

• Sample preparation: Incomplete denaturation or reducing conditions can affect protein migration.

• Gel percentage: Higher percentage gels provide better resolution for low molecular weight proteins like TEX12.

• Antibody specificity: Different antibodies targeting different epitopes might detect specific isoforms or modified forms of TEX12.

To address this issue:

• Use a protein ladder covering the low molecular weight range

• Include positive controls with known TEX12 expression

• Validate with multiple antibodies targeting different regions of TEX12

• Consider using TEX12-overexpressing samples as reference controls

If consistent discrepancies are observed, western blot combined with mass spectrometry could help identify if the detected protein is indeed TEX12 or a related protein.

How can I improve signal-to-noise ratio when using TEX12 antibodies in immunohistochemistry?

To improve signal-to-noise ratio in TEX12 immunohistochemistry:

• Optimize antigen retrieval: Use TE buffer pH 9.0 as recommended for TEX12, though citrate buffer pH 6.0 may be used as an alternative .

• Titrate antibody concentration: Start with the recommended dilution range (1:50-1:500 for IHC) and perform a dilution series to determine optimal concentration .

• Block adequately: Use 5-10% normal serum from the species of the secondary antibody, with the addition of 0.1-0.3% Triton X-100 for improved penetration.

• Increase washing steps: Add additional washing steps with PBS or TBS containing 0.05-0.1% Tween-20.

• Use high-quality secondary detection systems: Consider using polymer-based detection systems for enhanced sensitivity and reduced background.

• Include proper controls: Always run parallel negative controls (omitting primary antibody) and positive controls (testis tissue) to assess background and specific staining .

• Consider fluorescent detection: For co-localization studies, fluorescent detection may offer better signal discrimination than chromogenic methods.

If high background persists, pre-absorbing the antibody with tissue homogenate from a TEX12-negative tissue may help reduce non-specific binding.

What could cause inconsistent staining patterns with TEX12 antibodies in cancer cell lines?

Inconsistent TEX12 staining patterns in cancer cell lines may result from:

• Heterogeneous expression: TEX12 expression can vary within cancer cell populations, particularly in non-clonal lines.

• Cell cycle dependence: Since TEX12 affects centrosome function, its expression or localization may vary through the cell cycle.

• Fixation sensitivity: Different fixation methods may preserve epitopes differently. Compare 4% PFA, methanol, and methanol-acetone fixation to determine optimal conditions.

• Antibody specificity: Different antibodies target different epitopes and may reveal distinct localization patterns. In the Feichtinger et al. study, commercial TEX12 antibodies were validated to confirm specificity .

• Culture conditions: Confluence, serum levels, and oxygen tension may affect TEX12 expression.

To address inconsistencies:

• Standardize cell culture and fixation conditions

• Use multiple antibodies targeting different epitopes

• Include siRNA knockdown controls to confirm specificity

• Consider single-cell approaches (like flow cytometry) to quantify heterogeneity

• Perform co-localization studies with established markers (e.g., centrosomal markers if studying centrosomal TEX12)

How should results be interpreted when TEX12 is detected in normally TEX12-negative cell types?

When TEX12 is detected in reportedly negative cell types:

• Validate antibody specificity: Confirm specificity using knockdown controls or competitive blocking with immunizing peptide .

• Consider sensitivity limits: More sensitive detection methods might reveal low-level expression previously undetected.

• Evaluate biological context: TEX12 expression in cancer follows different patterns than in normal tissues. Remember that TEX12 is normally testis-specific but becomes aberrantly expressed in various cancers .

• Assess functional relevance: In the Feichtinger et al. study, TEX12-negative PEO1 cancer cells showed no response to TEX12 silencing, suggesting that even if low levels are present, they may not be functionally relevant .

• Investigate regulation mechanisms: Consider examining epigenetic regulation (DNA methylation, histone modifications) of the TEX12 promoter in these cells.

• Verify at multiple levels: Confirm expression at both mRNA (RT-qPCR) and protein (Western blot, immunofluorescence) levels .